Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Intraoperative Opioid Use and a Combined Anesthesia Regimen in Patients Undergoing Radical Prostatectomy for Prostate Cancer in a Single-Center Cohort.

Journal of clinical medicine·2025
Same author

Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.

Frontiers in pharmacology·2024
Same author

Trends and outcomes of hospitalized patients with priapism in Germany: results from the GRAND study.

International journal of impotence research·2024
Same author

Perioperative outcomes of penile prosthesis implantation in Germany: results from the GRAND study.

International journal of impotence research·2023
Same author

Is cortisol an endogenous mediator of erectile dysfunction in the adult male?

Translational andrology and urology·2023
Same author

[Urinary diversion for acute epididymitis : Transurethral or suprapubic catheter?]

Urologie (Heidelberg, Germany)·2022
Same journal

[Transition in Differences of Sex Development (DSD): From Human Being to Person].

Aktuelle Urologie·2026
Same journal

[Posterior Urethral Valves: A Pediatric Urological Condition with Lifelong Relevance].

Aktuelle Urologie·2026
Same journal

[Current Developments and Strategies for Infection Prevention and Management in Penile Implant Surgery].

Aktuelle Urologie·2026
Same journal

[Transition of Patients with Neurogenic Bladder Dysfunction: Challenges and Unmet Needs in Adult Care].

Aktuelle Urologie·2026
Same journal

[Hypospadias: A Long-Term Problem?]

Aktuelle Urologie·2026
Same journal

[Urogenital Symptoms in Cyclists and Reduction of Perineal Pressure Load Using a Prostate Volume-Adapted Bicycle Saddle].

Aktuelle Urologie·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

[Erectile dysfunction after radical prostatectomy].

Armin J Becker1, C G Stief, T C Stadler

  • 1Ludwig-Maximilians-Universität (LMU) München, Medizinische Fakultät, Klinikum Grosshadern, Urologische Klinik & Poliklinik, München. armin.becker@med.unimuenchen.de

Aktuelle Urologie
|September 5, 2009
PubMed
Summary
This summary is machine-generated.

Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating erectile dysfunction (ED) after prostate cancer surgery. Early administration and testosterone therapy can improve outcomes and are safe when indicated.

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jun 20, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Area of Science:

  • Urology
  • Oncology
  • Andrology

Context:

  • Nerve-sparing radical prostatectomy has reduced erectile dysfunction (ED) rates.
  • Surgical techniques (open, laparoscopic, robotic) show no distinct advantage for ED.
  • Phosphodiesterase type 5 (PDE5) inhibitors are first-line ED treatment if no contraindications exist.

Purpose:

  • To review current therapeutic strategies for managing erectile dysfunction (ED) post-prostatectomy.
  • To evaluate the efficacy and safety of various ED treatments, including pharmacotherapy and hormone replacement.

Summary:

  • PDE5 inhibitors are the gold standard for first-line ED treatment post-prostatectomy, particularly when administered early.
  • Second-line options include intraurethral prostaglandin E1 and intracavernosal injections.
  • Penile prosthesis implantation is a third-line, last-resort option.
  • Testosterone substitution therapy can alleviate hypogonadal symptoms and improve ED after prostate cancer treatment, with a favorable safety profile when carefully indicated.

Impact:

  • Establishes PDE5 inhibitors as a highly effective early intervention for post-prostatectomy ED.
  • Highlights the safety and potential benefits of testosterone therapy in selected prostate cancer survivors.
  • Provides a tiered treatment approach for managing ED in this patient population.